Enter Glenmark Pharma, says SP Tulsian

SP Tulsian of sptulsian.com told CNBC-TV18, "Looking to the commentary, if you really see the topline growth of Glenmark Pharma that has really impressed. One may argue or one can question about the margins, but I don’t think that if you have a topline growth also margins may follow in the subsequent quarters that is number one on the Q4 numbers, if you go by the management commentary I have not seen management to be so confident, Glenn Saldanha has stated that you are going to see the excellent numbers going ahead and that itself is quite positive commentary having come on the guidance of the company not for one quarter, but for whole of FY17.""Thirdly, I don’t think that there is any meaning in taking 52-week high of the pharma stocks because you have seen the 52-week high touching for all the stocks in a frenzy, so even if you get a return of about 15 percent on these pharma stocks and if you see the confident and positive commentary coming in from the management, this is the right time to enter and I am actually expecting may be one can look for a 15 percent return in 3-4 months time if you have a short term investment view.""As a trader probably, I may not advise to go long in the May series may be June could be the right, if one can have a position in the June series in the stock that will be better because May not be able to give you that kind of a return or you will look to create your long position in May and rollover at near expiry."